6
项与 Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) 相关的临床试验A Prospective, Non-inferiority Study Comparing VRD±D Followed by BCMA CAR-T Cell Therapy Versus VRD±D Followed by Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Patients With Newly-diagnosed Multiple Myeloma
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Safety and Efficiency of VRd Combining BCMA CAR-T Regimen for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.
This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT. A total of 40 subjects will be enrolled into this study.
100 项与 Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) 相关的临床结果
100 项与 Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) 相关的转化医学
100 项与 Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) 相关的专利（医药）
100 项与 Anti-BCMA CAR-T(Institute of Hematology & Blood Diseases Hospital) 相关的药物交易
